Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2025 | Where is ALL therapy moving based on ASH 2025 abstracts?

Marlise Luskin • 6 Dec 2025
ASH 2025
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab CAR-T Inotuzumab ozogamicin

In this video, Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, briefly discusses where the field of acute lymphoblastic leukemia (ALL) is moving based on recent data and presentations at the ASH 2025 meeting, noting that treatment is improving due to advances in therapies in both the first-line and relapsed settings. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Marlise Luskin

Understanding the evolving treatment landscape of Ph+ ALL in the US
1:19
Understanding the evolving treatment landscape of Ph+ ALL in the US
Marlise Luskin • 6 Dec 2025
A Phase I study of venetoclax plus inotuzumab ozogamicin for R/R ALL
2:33
A Phase I study of venetoclax plus inotuzumab ozogamicin for R/R ALL
Marlise Luskin • 6 Dec 2025
A Phase I study of asciminib combined with dasatinib, prednisone, and blinatumomab for Ph+ ALL
2:11
A Phase I study of asciminib combined with dasatinib, prednisone, and blinatumomab for Ph+ ALL
Marlise Luskin • 29 May 2025
Advice for fellows and early-career investigators
0:51
Advice for fellows and early-career investigators
Marlise Luskin • 29 May 2025

Related Videos

The impact of baseline gene aberrations on PFS and OS in patients with CLL in the FLAIR trial
4:05
The impact of baseline gene aberrations on PFS and OS in patients with CLL in the FLAIR trial
Marlise Luskin • 13 Jan 2026
Real-world treatment patterns and biomarker use in patients aged ≥65 yrs with CLL/SLL from 2020-2024
4:10
Real-world treatment patterns and biomarker use in patients aged ≥65 yrs with CLL/SLL from 2020-2024
Marlise Luskin • 8 Dec 2025
The global ABNL-MARRO trials and revised response criteria for MDS/MPN overlap syndromes
1:24
The global ABNL-MARRO trials and revised response criteria for MDS/MPN overlap syndromes
Marlise Luskin • 6 Dec 2025
A novel remote monitoring system to support outpatient administration of bispecific T-cell engagers
2:35
A novel remote monitoring system to support outpatient administration of bispecific T-cell engagers
Marlise Luskin • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals